Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.^1,2In oncology, the agency has authorized biosimilar versions of the therapeutic monoclonal antibodies trastuzumab (Herceptin), bevacizumab (Avastin), and rituximab (Rituxan), as well as biosimilars for the supportive care agents pegfilgrastim (Neulasta), f ilgrastim (Neupogen), and epoetin-alfa (Epogen).

Continue reading on Oncology Live.